Avi Minkowitz was named Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc., succeeding David Lazar. As of November 14, 2026, KALA BIO, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 2, 2026 to February 20, 2026, naming 1 appointment and 2 departures (Form 8-K, February 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like KALA BIO, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: David Lazar · Role: Director · 8-K, 2026-02-20
- · In / out: Out · Person: David Lazar · Role: Chief Executive Officer and Chief Financial Officer · 8-K, 2026-02-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-02
KALA BIO, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-02 to 2026-02-20. They name 2 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as KALA BIO, Inc. files it.
Layoffs on record: about 19 jobs, latest 2025-10-20 (layoff filings and notices).
Also on the record for KALA BIO, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Stake report, Schedule 13G, by Labkowski Nachum | 5% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D/A, by Lazar David E. | 3.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 0.01% of the class | 5%+ stakes | Source |
| March 17, 2026 | Form D, private offering | $1.75M sold | Form D page | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 9.99% of the class | 5%+ stakes | Source |
| February 13, 2026 | Form D, private offering | $2.25M sold | Form D page | Source |
| February 6, 2026 | Stake report, Schedule 13D, by David E. Lazar | 5.18% of the class | 5%+ stakes | Source |
| January 13, 2026 | Stake report, Schedule 13G, by LifeSci Capital LLC | 7.9% of the class | 5%+ stakes | Source |
| December 3, 2025 | Stake report, Schedule 13G, by OXFORD FINANCE LLC | 16.5% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs KALA BIO, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on KALA BIO, Inc. and the records around it.
KALA BIO, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Mar 2026
- Form D filing Mar 2026
- Form D filing Feb 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- SR One Capital Fund II Aggregator, LP also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- David E. Lazar also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Watch KALA BIO, Inc.
Get an email when KALA BIO, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on KALA BIO, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on KALA BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on KALA BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-20 | Out | Director | 8-K, 2026-02-20 | ||
| 2026-02-05 | Out | Chief Executive Officer and Chief Financial Officer | 8-K, 2026-02-05 | ||
| 2026-02-05 | In | Chief Executive Officer and Chief Financial Officer | 8-K, 2026-02-05 | ||
| 2026-02-02 | Reported | not named in the filing | 8-K, 2026-02-02 |
Why did they leave? What the filings say
KALA BIO, Inc.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- David Lazar, Director (filed 2026-02-20): the filing states no reason.
- David Lazar, Chief Executive Officer and Chief Financial Officer (filed 2026-02-05): the filing states no reason.
Who leads KALA BIO, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David Lazar, departure reported (filed 2026-02-20). No successor is named in these filings.
- Chief Executive Officer and Chief Financial Officer: David Lazar, departure reported (filed 2026-02-05). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on KALA BIO, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch KALA BIO, Inc. (free up to 3)
Find people with the same kind of experience as the Director at KALA BIO, Inc., with the record behind each one.
Find candidates like Director at KALA BIO, Inc.Every change, in the filing's words
Departing: David Lazar, Director
On February 16, 2026, David Lazar notified KALA BIO, Inc. (the " Company ") of his decision to resign as a member of the Board of Directors of the Company, effective as of the same date.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Departing: David Lazar, Chief Executive Officer and Chief Financial Officer
On February 2, 2026, David Lazar tendered his resignation to the Board of the Directors (the " Board ") as the Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc. (the " Company "), effective as of the same date.
Appointed: Avi Minkowitz, Chief Executive Officer and Chief Financial Officer
On February 2, 2026, to fill the executive vacancy as a result of Mr. Lazar's resignation as the Chief Executive Officer and Chief Financial Officer of the Company, the Board appointed Avi Minkowitz, a current director of the Company, as the Company's Chief Executive Officer and Chief Financial Officer, effective as of the same date.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Mr. Lazar remains a director of the Board.
- Prior to his appointment as the Company's Chief Executive Officer and Chief Financial Officer, Mr. Minkowitz served as Vice President at Parkit Enterprise Inc. (TSX: PKT.V), now an industrial real estate platform, from July 2018 to December 2020.
- In that capacity, he sourced and underwrote potential real estate acquisitions for the Company.
- His tenure ended with the successful underwriting and merger with an industrial real estate entity.
- He subsequently served as an Analyst at Leonite Capital, a family office investment firm, from January 2021 to October 2024, where he focused primarily on financing for publicly traded companies, M&A, and business development.
- In addition, since 2023, he has worked as a Management Consultant, advising companies on growth, restructuring, and financing.
- Mr. Minkowitz currently serves on the board of directors at NuRAN Wireless Inc. (CSE: NUR) beginning in November 2025, and of International Star Inc. (OTC: ILST) beginning in October 2022.
Reported
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.
KALA BIO, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for KALA BIO, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
